Aldaba Josephine G, Llave Cecilia L, Uy Ma Esterlita V, Tejano Kim Patrick, Aquino Ma Romina C, Antonio P Catalig Migel, Sy Alvin Duke R, Valverde Haidee A, Mooney Jessica, Slavkovsky Rose
Institute of Child Health and Human Development, University of the Philippines Manila-National Institutes of Health, Manila, Philippines.
Disease Prevention and Control Bureau, Department of Health, Manila, Philippines.
Vaccine X. 2024 Feb 18;17:100459. doi: 10.1016/j.jvacx.2024.100459. eCollection 2024 Mar.
The World Health Organization has recommended the inclusion of human papillomavirus (HPV) vaccines in national immunization programs to address the global problem of cervical cancer. In the Philippines, HPV vaccination was introduced in a phased approach in 2015. This study seeks to estimate the cost of delivery of the HPV vaccination program and its operational context in the Philippines.
This was a retrospective, cross-sectional micro-costing study focused on ongoing HPV vaccination delivery and its operational context across all levels of the health system. Using structured questionnaires and data collection from secondary sources, the weighted mean financial and economic costs and costs per dose at the national, subnational, and health facility levels were estimated.
The weighted mean financial and economic costs per dose of the HPV vaccination program aggregated across all levels of the health system were $US3.72and $29.74, respectively. Activities contributing most significantly to costs were service delivery and vaccine collection or distribution and storage at the health facility and administrative levels, respectively. The opportunity costs for health worker and non-health worker time accounted for 77% of the economic cost per dose.
The total weighted mean financial and economic costs of HPV delivery are within range of those reported in other countries. Costing studies can help identify cost drivers with local operational context to help inform policymakers and program managers in budgeting and planning interventions to improve program implementation.
世界卫生组织建议将人乳头瘤病毒（HPV）疫苗纳入国家免疫规划，以应对宫颈癌这一全球性问题。在菲律宾，HPV疫苗接种于2015年分阶段推行。本研究旨在估算菲律宾HPV疫苗接种项目的实施成本及其运营背景。
这是一项回顾性横断面微观成本研究，重点关注卫生系统各级正在进行的HPV疫苗接种及其运营背景。通过结构化问卷和二手资料数据收集，估算了国家、国家以下和卫生机构层面的加权平均财务成本、经济成本及每剂成本。
卫生系统各级HPV疫苗接种项目每剂的加权平均财务成本和经济成本分别为3.72美元和29.74美元。对成本贡献最大的活动分别是卫生机构层面的服务提供以及卫生机构和行政层面的疫苗采集、分发和储存。卫生工作者和非卫生工作者时间的机会成本占每剂经济成本的77%。
HPV疫苗接种的加权平均财务成本和经济成本总额在其他国家报告的范围内。成本研究有助于确定当地运营背景下的成本驱动因素，从而为政策制定者和项目管理者在预算编制和规划干预措施以改善项目实施方面提供参考。
